Join Growin Stock Community!

Bio-techne corporationTECH.US Overview

US StockHealthcare
(No presentation for TECH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TECH AI Insights

TECH Overall Performance

TECH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TECH Recent Performance

-2.39%

Bio-techne corporation

0.05%

Avg of Sector

-0.31%

S&P500

TECH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TECH Key Information

TECH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TECH Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Price of TECH

TECH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TECH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.52
PE Ratio (TTM)
111.32
Forward PE
25.39
PS Ratio (TTM)
7.59
PB Ratio
4.51
Price-to-FCF
40.56
METRIC
VALUE
vs. INDUSTRY
Gross Margin
65.22%
Net Margin
6.67%
Revenue Growth (YoY)
1.64%
Profit Growth (YoY)
1.01%
3-Year Revenue Growth
2.90%
3-Year Profit Growth
1.42%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.52
PE Ratio (TTM)
111.32
Forward PE
25.39
PS Ratio (TTM)
7.59
PB Ratio
4.51
Price-to-FCF
40.56
Gross Margin
65.22%
Net Margin
6.67%
Revenue Growth (YoY)
1.64%
Profit Growth (YoY)
1.01%
3-Year Revenue Growth
2.90%
3-Year Profit Growth
1.42%

  • When is TECH's latest earnings report released?

    The most recent financial report for Bio-techne corporation (TECH) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TECH's short-term business performance and financial health. For the latest updates on TECH's earnings releases, visit this page regularly.

  • Where does TECH fall in the P/E River chart?

    According to historical valuation range analysis, Bio-techne corporation (TECH)'s current price-to-earnings (P/E) ratio is 132.47, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of TECH?

    According to the latest financial report, Bio-techne corporation (TECH) reported an Operating Profit of 54.46M with an Operating Margin of 18.41% this period, representing a growth of 14.85% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TECH's revenue growth?

    In the latest financial report, Bio-techne corporation (TECH) announced revenue of 295.88M, with a Year-Over-Year growth rate of -0.39%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TECH have?

    As of the end of the reporting period, Bio-techne corporation (TECH) had total debt of 350.9M, with a debt ratio of 0.14. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TECH have?

    At the end of the period, Bio-techne corporation (TECH) held Total Cash and Cash Equivalents of 172.88M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does TECH go with three margins increasing?

    In the latest report, Bio-techne corporation (TECH) achieved the “three margins increasing” benchmark, with a gross margin of 64.6%%, operating margin of 18.41%%, and net margin of 12.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TECH's profit trajectory and future growth potential.

  • Is TECH's EPS continuing to grow?

    According to the past four quarterly reports, Bio-techne corporation (TECH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TECH?

    Bio-techne corporation (TECH)'s Free Cash Flow (FCF) for the period is 76.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TECH?

    The latest valuation data shows Bio-techne corporation (TECH) has a Price-To-Earnings (PE) ratio of 132.47 and a Price/Earnings-To-Growth (PEG) ratio of -15.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.